Search company, investor...

Predict your next investment

RiverVest Venture Partners company logo
Venture Capital
rivervest.com

Investments

130

Portfolio Exits

34

Funds

9

About RiverVest Venture Partners

RiverVest Venture Partners focuses exclusively on life sciences, in particular in the medical device and biopharmaceutical industries. RiverVest also invests in select later-stage life science companies to diversify risk and maximize portfolio returns. Since its inception in September 2000, RiverVest has raised 2 investment funds with total committed capital of $164 million, and supported more than 20 life science companies.

Headquarters Location

101 South Hanley Road Suite 1850

St. Louis, Missouri, 63105,

United States

314-726-6700

Want to inform investors similar to RiverVest Venture Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest RiverVest Venture Partners News

OncoResponse: $13 Million Grant And $14 Million In Funding Received

Jun 5, 2023

OncoResponse – a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders – announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The company also concurrently raised $14 million in new funding from existing investors, led by RiverVest Venture Partners and including ARCH Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, InterVest and others. The CPRIT award and investment is going to support the advancement of OR502, a best-in-class anti-LILRB2 antibody poised to move to IND and clinical studies. And the funds from the existing syndicate will also support continued advancement of the company’s lead immunotherapy candidate OR2805, a fully human monoclonal antibody identified from an Elite Responder using OncoResponse’s proprietary B-cell discovery platform. OR2805 is currently being evaluated in a Phase 1 clinical trial. KEY QUOTES: “We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders. We are excited by the data generated to date supporting the ability of OR502 to modulate inhibitory macrophages in the tumor microenvironment and induce anti-tumor activity.” — Clifford Stocks, Chief Executive Officer of OncoResponse “We are pleased to support OncoResponse in their efforts to develop new and innovative immunotherapy treatments for cancer. The company has made significant progress in building their pipeline and we look forward to further insights from future clinical studies.” — John McKearn, PhD, Managing Director of RiverVest Venture Partners Trending on Pulse 2.0

RiverVest Venture Partners Investments

130 Investments

RiverVest Venture Partners has made 130 investments. Their latest investment was in OncoResponse as part of their Series D on May 5, 2023.

CBI Logo

RiverVest Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/12/2023

Series D

OncoResponse

$14M

No

3

1/27/2023

Series C

Alleviant Medical

$75M

Yes

15

11/15/2022

Series A

Bonum Therapeutics

$93M

No

11

8/16/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

12/22/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/12/2023

1/27/2023

11/15/2022

8/16/2022

12/22/2021

Round

Series D

Series C

Series A

Series B

Series B

Company

OncoResponse

Alleviant Medical

Bonum Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$14M

$75M

$93M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

15

11

10

10

RiverVest Venture Partners Portfolio Exits

34 Portfolio Exits

RiverVest Venture Partners has 34 portfolio exits. Their latest portfolio exit was Cardialen on December 14, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/14/2022

Acquired

$99M

2

9/7/2022

Acquired

$99M

14

8/22/2022

Acquired

$99M

16

10/22/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

4/28/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/14/2022

9/7/2022

8/22/2022

10/22/2021

4/28/2021

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

14

16

10

10

RiverVest Venture Partners Fund History

9 Fund Histories

RiverVest Venture Partners has 9 funds, including RiverVest Venture Fund V.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/23/2021

RiverVest Venture Fund V

$275M

3

12/18/2018

RiverVest Venture Fund IV

Subscribe to see more

Subscribe to see more

$99M

10

12/13/2016

Archer Seed Fund

Subscribe to see more

Subscribe to see more

$99M

10

11/18/2016

3x5 RiverVest Fund II

Subscribe to see more

Subscribe to see more

$99M

10

5/5/2015

RiverVest Venture Fund III

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/23/2021

12/18/2018

12/13/2016

11/18/2016

5/5/2015

Fund

RiverVest Venture Fund V

RiverVest Venture Fund IV

Archer Seed Fund

3x5 RiverVest Fund II

RiverVest Venture Fund III

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$275M

$99M

$99M

$99M

$99M

Sources

3

10

10

10

10

RiverVest Venture Partners Team

13 Team Members

RiverVest Venture Partners has 13 team members, including current Founder, Managing Director, Thomas C. Melzer.

Name

Work History

Title

Status

Thomas C. Melzer

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Thomas C. Melzer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Director

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.